AP830A - Indole derivatives useful in therapy. - Google Patents
Indole derivatives useful in therapy. Download PDFInfo
- Publication number
- AP830A AP830A APAP/P/1997/000982A AP9700982A AP830A AP 830 A AP830 A AP 830A AP 9700982 A AP9700982 A AP 9700982A AP 830 A AP830 A AP 830A
- Authority
- AP
- ARIPO
- Prior art keywords
- alkyl
- formula
- reaction
- independently represent
- compound
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title description 5
- 229940054051 antipsychotic indole derivative Drugs 0.000 title description 4
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 abstract description 46
- 125000000217 alkyl group Chemical group 0.000 abstract description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 11
- 229910052736 halogen Inorganic materials 0.000 abstract description 7
- 150000002367 halogens Chemical class 0.000 abstract description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract description 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 125000003342 alkenyl group Chemical group 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 abstract description 3
- 125000001624 naphthyl group Chemical group 0.000 abstract description 3
- 125000000304 alkynyl group Chemical group 0.000 abstract description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract description 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 101100276977 Caenorhabditis elegans dapk-1 gene Proteins 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 230000002411 adverse Effects 0.000 description 11
- -1 alkali metal salts Chemical class 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 239000002841 Lewis acid Substances 0.000 description 7
- 150000007517 lewis acids Chemical class 0.000 description 7
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000004795 grignard reagents Chemical class 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 229910000077 silane Inorganic materials 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical group CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- BSHZKBGFYKXEDS-UHFFFAOYSA-N (4-chlorophenyl)-indol-1-ylmethanone Chemical class C1=CC(Cl)=CC=C1C(=O)N1C2=CC=CC=C2C=C1 BSHZKBGFYKXEDS-UHFFFAOYSA-N 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000002308 endothelin receptor antagonist Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- ABUKMOCUMIPDHV-UHFFFAOYSA-N 2-phenoxy-2-phenylacetic acid Chemical class C=1C=CC=CC=1C(C(=O)O)OC1=CC=CC=C1 ABUKMOCUMIPDHV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229950005228 bromoform Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical compound O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 description 1
- JNGDFYLGDPAEBY-UHFFFAOYSA-N oxadiazole-4-thione Chemical compound S=C1CON=N1 JNGDFYLGDPAEBY-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical compound O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 description 1
- QPDUQKTYZRXRBC-UHFFFAOYSA-N triazole-4-thione Chemical compound S=C1C=NN=N1 QPDUQKTYZRXRBC-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9609641.7A GB9609641D0 (en) | 1996-05-09 | 1996-05-09 | Compounds useful in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9700982A0 AP9700982A0 (en) | 1997-07-31 |
| AP830A true AP830A (en) | 2000-05-03 |
Family
ID=10793387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1997/000982A AP830A (en) | 1996-05-09 | 1997-05-08 | Indole derivatives useful in therapy. |
Country Status (42)
| Country | Link |
|---|---|
| US (4) | US6017945A (is) |
| EP (1) | EP0901470B1 (is) |
| JP (1) | JP3245179B2 (is) |
| KR (1) | KR100331217B1 (is) |
| CN (1) | CN1124262C (is) |
| AP (1) | AP830A (is) |
| AR (1) | AR007030A1 (is) |
| AT (1) | ATE263151T1 (is) |
| AU (1) | AU717849B2 (is) |
| BG (1) | BG102873A (is) |
| BR (1) | BR9709072A (is) |
| CA (1) | CA2253876A1 (is) |
| CO (1) | CO4650036A1 (is) |
| CZ (1) | CZ292928B6 (is) |
| DE (1) | DE69728392T2 (is) |
| DK (1) | DK0901470T3 (is) |
| DZ (1) | DZ2227A1 (is) |
| EA (1) | EA001471B1 (is) |
| ES (1) | ES2218675T3 (is) |
| GB (1) | GB9609641D0 (is) |
| HN (1) | HN1997000058A (is) |
| HR (1) | HRP970249B1 (is) |
| HU (1) | HUP9901245A3 (is) |
| ID (1) | ID16878A (is) |
| IL (1) | IL125903A0 (is) |
| IS (1) | IS1856B (is) |
| MA (1) | MA26428A1 (is) |
| NO (1) | NO312547B1 (is) |
| NZ (1) | NZ332640A (is) |
| OA (1) | OA10896A (is) |
| PE (1) | PE65098A1 (is) |
| PL (1) | PL329725A1 (is) |
| PT (1) | PT901470E (is) |
| SI (1) | SI0901470T1 (is) |
| SK (1) | SK150398A3 (is) |
| TN (1) | TNSN97078A1 (is) |
| TR (1) | TR199802269T2 (is) |
| TW (1) | TW491838B (is) |
| UA (1) | UA50767C2 (is) |
| UY (1) | UY24546A1 (is) |
| WO (1) | WO1997043260A1 (is) |
| ZA (1) | ZA973963B (is) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722287D0 (en) * | 1997-10-22 | 1997-12-17 | Pfizer Ltd | Compounds useful in therapy |
| CZ305827B6 (cs) | 1999-02-10 | 2016-03-30 | Astrazeneca Ab | Indolové deriváty |
| US20050203166A1 (en) * | 2000-06-30 | 2005-09-15 | Cancer Research Technology Limited | Indole-3-acetic acid derivatives |
| GB0016162D0 (en) * | 2000-06-30 | 2000-08-23 | Cancer Res Campaign Tech | Indole-3-acetic acid derivatives |
| TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| ES2290318T3 (es) | 2001-06-20 | 2008-02-16 | Wyeth | Derivados sustituidos de acido indolico como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1). |
| AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| DK1569899T3 (da) | 2002-12-10 | 2006-10-23 | Wyeth Corp | Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1) |
| CN1726191A (zh) | 2002-12-10 | 2006-01-25 | 惠氏公司 | 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代的吲哚氧代－乙酰氨基乙酸衍生物 |
| MXPA05006283A (es) | 2002-12-10 | 2005-08-19 | Wyeth Corp | Derivados de arilo, ariloxi, y alquiloxi del acido sustituido 1h-indol-3-il glicoxilico como inhibidores del inhibidor-1 activador de plasminogeno (pai-1). |
| MXPA05006288A (es) | 2002-12-10 | 2005-08-19 | Wyeth Corp | Derivados del acido 3-carbonil-1h-indol-1-ilacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1). |
| UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| WO2004067529A1 (en) * | 2003-01-22 | 2004-08-12 | Eli Lilly And Company | Indole-derivative modulators of steroid hormone nuclear receptors |
| US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
| US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
| US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
| US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
| US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| JP2005109006A (ja) * | 2003-09-29 | 2005-04-21 | Tdk Corp | 高電圧貫通型コンデンサ及びマグネトロン |
| HN2004000536A (es) * | 2003-12-16 | 2009-02-18 | Wyeth Corp | Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles |
| KR20070055563A (ko) | 2004-08-23 | 2007-05-30 | 와이어쓰 | 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산 |
| AU2005277137A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as PAI-1 inhibitors |
| BRPI0514572A (pt) | 2004-08-23 | 2008-06-17 | Wyeth Corp | ácidos de tiazolo-naftila |
| MX2008002117A (es) | 2005-08-17 | 2008-09-26 | Wyeth Corp | Indoles sustituidos y metodos de uso de estos. |
| RU2435585C2 (ru) * | 2006-04-13 | 2011-12-10 | Актелион Фармасьютиклз Лтд | Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких |
| DE102008030207A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | Compounds for increasing neural plasticity |
| CN106674065A (zh) * | 2016-12-07 | 2017-05-17 | 贵州大学 | 一种5‑卤代‑2‑烷氧基‑4‑甲苯磺酰氯制备方法 |
| GB201817038D0 (en) * | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| WO2020176599A1 (en) | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | Azepino-indoles and other heterocycles for treating brain disorders |
| AU2022416279A1 (en) | 2021-12-15 | 2024-07-25 | Delix Therapeutics, Inc. | Phenoxy and benzyloxy substituted psychoplastogens and uses thereof |
| CN117263832A (zh) * | 2023-08-18 | 2023-12-22 | 辽宁龙田化工科技有限公司 | 一种2-氯-4-甲磺酰基苯甲酸合成方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014434A1 (en) * | 1992-12-22 | 1994-07-07 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| EP0617001A1 (en) * | 1993-03-19 | 1994-09-28 | Merck & Co. Inc. | Phenoxyphenylacetic acid derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637352A (is) * | 1962-09-14 | |||
| GB1255518A (en) * | 1968-10-08 | 1971-12-01 | Sumitomo Chemical Co | 2-indolylacetic acid derivatives and process for production thereof |
| US4397079A (en) * | 1981-03-30 | 1983-08-09 | International Business Machines Corp. | Process for improving the yield of integrated devices including Schottky barrier diodes |
| US5245046A (en) * | 1988-11-14 | 1993-09-14 | The Upjohn Company | α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
| AU8641991A (en) | 1990-09-10 | 1992-03-30 | Rhone-Poulenc Rorer International (Holdings) Inc. | Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| GB9317096D0 (en) * | 1993-08-17 | 1993-09-29 | Pfizer Ltd | Indoles |
-
1996
- 1996-05-09 GB GBGB9609641.7A patent/GB9609641D0/en active Pending
-
1997
- 1997-04-01 TW TW086104171A patent/TW491838B/zh not_active IP Right Cessation
- 1997-04-11 CZ CZ19983582A patent/CZ292928B6/cs not_active IP Right Cessation
- 1997-04-11 ES ES97920690T patent/ES2218675T3/es not_active Expired - Lifetime
- 1997-04-11 JP JP54042397A patent/JP3245179B2/ja not_active Expired - Fee Related
- 1997-04-11 US US09/147,096 patent/US6017945A/en not_active Expired - Fee Related
- 1997-04-11 TR TR1998/02269T patent/TR199802269T2/xx unknown
- 1997-04-11 IL IL12590397A patent/IL125903A0/xx unknown
- 1997-04-11 SI SI9730646T patent/SI0901470T1/xx unknown
- 1997-04-11 KR KR1019980709023A patent/KR100331217B1/ko not_active Expired - Fee Related
- 1997-04-11 DE DE1997628392 patent/DE69728392T2/de not_active Expired - Fee Related
- 1997-04-11 AT AT97920690T patent/ATE263151T1/de not_active IP Right Cessation
- 1997-04-11 CN CN97194016A patent/CN1124262C/zh not_active Expired - Fee Related
- 1997-04-11 DK DK97920690T patent/DK0901470T3/da active
- 1997-04-11 PL PL97329725A patent/PL329725A1/xx unknown
- 1997-04-11 SK SK1503-98A patent/SK150398A3/sk unknown
- 1997-04-11 UA UA98115906A patent/UA50767C2/uk unknown
- 1997-04-11 EA EA199800908A patent/EA001471B1/ru not_active IP Right Cessation
- 1997-04-11 AU AU26978/97A patent/AU717849B2/en not_active Ceased
- 1997-04-11 HU HU9901245A patent/HUP9901245A3/hu unknown
- 1997-04-11 NZ NZ332640A patent/NZ332640A/en unknown
- 1997-04-11 EP EP97920690A patent/EP0901470B1/en not_active Expired - Lifetime
- 1997-04-11 CA CA002253876A patent/CA2253876A1/en not_active Abandoned
- 1997-04-11 WO PCT/EP1997/001882 patent/WO1997043260A1/en active IP Right Grant
- 1997-04-11 PT PT97920690T patent/PT901470E/pt unknown
- 1997-04-11 BR BR9709072A patent/BR9709072A/pt active Search and Examination
- 1997-04-29 HN HN1997000058A patent/HN1997000058A/es unknown
- 1997-05-02 PE PE1997000345A patent/PE65098A1/es not_active Application Discontinuation
- 1997-05-07 AR ARP970101888A patent/AR007030A1/es not_active Application Discontinuation
- 1997-05-07 MA MA24599A patent/MA26428A1/fr unknown
- 1997-05-07 TN TNTNSN97078A patent/TNSN97078A1/fr unknown
- 1997-05-07 CO CO97024471A patent/CO4650036A1/es unknown
- 1997-05-07 ID IDP971517A patent/ID16878A/id unknown
- 1997-05-07 UY UY24546A patent/UY24546A1/es not_active IP Right Cessation
- 1997-05-07 DZ DZ970074A patent/DZ2227A1/fr active
- 1997-05-08 ZA ZA973963A patent/ZA973963B/xx unknown
- 1997-05-08 AP APAP/P/1997/000982A patent/AP830A/en active
- 1997-05-09 HR HR970249A patent/HRP970249B1/xx not_active IP Right Cessation
-
1998
- 1998-08-28 IS IS4838A patent/IS1856B/is unknown
- 1998-10-09 OA OA9800192A patent/OA10896A/en unknown
- 1998-10-27 BG BG102873A patent/BG102873A/xx unknown
- 1998-11-09 NO NO19985225A patent/NO312547B1/no not_active IP Right Cessation
-
1999
- 1999-10-07 US US09/414,361 patent/US6136843A/en not_active Expired - Fee Related
-
2000
- 2000-04-24 US US09/556,651 patent/US6306852B1/en not_active Expired - Fee Related
-
2001
- 2001-01-09 US US09/756,835 patent/US6384070B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014434A1 (en) * | 1992-12-22 | 1994-07-07 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| EP0617001A1 (en) * | 1993-03-19 | 1994-09-28 | Merck & Co. Inc. | Phenoxyphenylacetic acid derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP830A (en) | Indole derivatives useful in therapy. | |
| Wang et al. | Facile synthesis of 3, 3-di (heteroaryl) indolin-2-one derivatives catalyzed by ceric ammonium nitrate (CAN) under ultrasound irradiation | |
| Hewawasam et al. | A general method for the synthesis of isatins: preparation of regiospecifically functionalized isatins from anilines | |
| JP2638752B2 (ja) | １−アミノエチルインドール誘導体 | |
| US4352811A (en) | 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles | |
| US2814625A (en) | 3-indolyl amino hydrocarbyl ketones | |
| Mąkosza et al. | Nucleophilic aromatic substitution of hydrogen as a tool for the synthesis of indole and quinoline derivatives | |
| Powers | Chloroindoles1 | |
| US6355642B1 (en) | Tetrahydrobenzindole compounds | |
| US4837235A (en) | Indole and indazole keto sulphones as leukotriene antagonists | |
| AU600813B2 (en) | Aliphatic carboxamides | |
| DE69107064T2 (de) | Indolderivate. | |
| Acheson | 1-Hydroxypyrroles, 1-hydroxyindoles and 9-hydroxycarbazoles | |
| Walser et al. | Synthesis and transformations of some 3-chloro-and 3-nitroindolenines | |
| JPH02188579A (ja) | インドリルイミダゾール誘導体 | |
| US6326501B1 (en) | Methylation of indole compounds using dimethyl carbonate | |
| DE3873562T2 (de) | Beta-alkylmelatonine. | |
| Black et al. | Synthesis and reactivity of 1-pyrroline-5-carboxylate ester 1-oxides | |
| Condie et al. | Regioselective reactivity of some 5, 7-dimethoxyindoles | |
| US2930797A (en) | 2-alkyl-3-indoleglyoxylamides | |
| Volk et al. | New One‐Pot Synthesis of 3‐Alkyl‐and 3‐(ψ‐Hydroxyalkyl) oxindoles from Isatins | |
| Hickman et al. | A concise synthesis of 3-hydroxyindole-2-carboxylates by a modified Baeyer–Villiger oxidation | |
| HU192416B (en) | Process for preparing indole derivatives and pharmaceutical compositions containing sucg compounds | |
| Flury et al. | 2, 2, 2‐Trifluoroethanol‐mediated hydroarylation of fluorinated alkynes with indoles: Application to diindolylmethanes | |
| US4603217A (en) | Ester substituted alkyl-2-(2,6-dichloroanilino)phenyl acetates |